Abo Enin Hadel A, El Nabarawy Nagla Ahmed, Elmonem Rehab A Abd
Pharmaceutics Department, National Organization of Drug Control and Research (NODCAR), Giza, Egypt.
National Egyptian Center of Environmental and Toxicological Research (NECTER), Cairo University, Cairo, Egypt.
AAPS PharmSciTech. 2017 Feb;18(2):563-575. doi: 10.1208/s12249-016-0533-z. Epub 2016 May 2.
The aim of this study was to develop a novel double-layer bi-medicated prolonged release mucoadhesive buccal film (MBF) containing lidocaine hydrochloride (LC) and diclofenac potassium (DK). The ultimate goal of the prepared system is the treatment of radiation-induced oral mucositis pain with improved patient acceptance. MBFs were prepared using 3 × 2 randomized full factorial design for film optimization. Nanoemulsion system (NES) was used to mask DK bitter taste. The prepared films were characterized, viz thickness, mass uniformity, surface pH, folding endurance, swelling studies, ex vivo bioadhesive strength, in vitro drug release, and ex vivo permeation. The in vivo evaluation was carried out by testing the anti-inflammatory and analgesic activities on rats followed by a clinical study on patients to prove their acceptance. The optimized MBF composed of 10% w/w HPMC-4KM, 50 mg LC, and 50 mg DK-NES was selected due to prolonged in vitro drug release pattern and ex vivo permeability (95.24 ± 2.14 and 93.48 ± 3.24% in 6 h, respectively). MBF exposed a strong anti-inflammatory effect from 61 to 87% inhibition with a strong analgesic effect when compared to DK® and LC®, respectively. The clinical study revealed that films were accepted by the patients, and the presence of LC on the outer side helped in pain feeling reduction while DK-NES in the inner side facilitated in rapidly relieving the inflammation effect.
本研究的目的是开发一种新型双层双药长效释放黏膜黏附口腔膜(MBF),其含有盐酸利多卡因(LC)和双氯芬酸钾(DK)。所制备系统的最终目标是治疗放射性口腔黏膜炎疼痛并提高患者接受度。采用3×2随机全因子设计制备MBF以优化成膜。使用纳米乳剂系统(NES)掩盖DK的苦味。对所制备的膜进行表征,即厚度、质量均匀性、表面pH值、耐折性、溶胀研究、体外生物黏附强度、体外药物释放和体外渗透。通过对大鼠进行抗炎和镇痛活性测试,随后对患者进行临床研究以证明其可接受性,从而进行体内评估。由于体外药物释放模式延长和体外渗透性良好(6小时内分别为95.24±2.14%和93.48±3.24%),选择了由10% w/w HPMC - 4KM、50 mg LC和50 mg DK - NES组成的优化MBF。与DK®和LC®相比,MBF分别表现出61%至87%抑制的强抗炎作用和强镇痛作用。临床研究表明,患者接受这些膜,外侧的LC有助于减轻疼痛感,而内侧的DK - NES有助于迅速减轻炎症效果。